AMERICAN CYANAMID's JACK BOWMAN MOVING TO JOHNSON & JOHNSON
Executive Summary
AMERICAN CYANAMID's JACK BOWMAN MOVING TO JOHNSON & JOHNSON to take responsibility for J&J's core pharmaceutical business. As a J&J company group chairman, Bowman will oversee McNeil Pharmaceutical Ortho Pharmaceutical, and Cilag, J&J's European pharmaceutical group. Bowman's resignation from American Cyanamid was announced July 21. He will officially join J&J on Aug. 1. At American Cyanamid, Bowman was executive vice president heading the $1.4 bil. medical group, consisting of Lederle pharmaceuticals and the medical device operations, including Davis & Geck. Under Bowman, the Cyanamid medical businesses have been growing rapidly. Medical group earnings in 1986 were up 28% to $184 mil. ("The Pink Sheet" May 18, p. 5). In the July 21 press release, American Cyanamid CEO George Sella said "Bowman leaves a long legacy of strong research and development, marketing, manufacturing and organization."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth